Regeneron Pharmaceuticals, Inc.: shareholders and insiders

REGNNASDAQHealthcare · Pharmaceutical Preparations

Price

$957.76

November 17, 2026Market cap $100B

What Ploutos Investor adds for Regeneron Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 18, 2025 to Nov 6, 2026, from their own Form 4 filings.

18 Form 4s

Bought on the market

–

nobody

Sold on the market

$58M

11 people

From Nov 18, 2025 to Nov 18, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan25%
  • The rest75%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 18, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·no buys·sold $57M by 11 people

  • 2025: no buys, sold $570.0K by 1 person
  • 2026: no buys, sold $57M by 11 people
  • Nov 4, 2026Jason PitofskySVP Controller
    Kind
  • Nov 4, 2026Jason PitofskySVP Controller
    Kind
  • Nov 4, 2026Jason PitofskySVP Controller
    Kind
  • Nov 4, 2026Jason PitofskySVP Controller
    Kind
  • Nov 4, 2026Jason PitofskySVP Controller
    Kind
  • Nov 4, 2026Jason PitofskySVP Controller
    Kind
  • Nov 4, 2026Jason PitofskySVP Controller
    Kind
  • Nov 4, 2026Jason PitofskySVP Controller
    Kind
  • Nov 4, 2026Jason PitofskySVP Controller
    Kind
  • Nov 4, 2026Jason PitofskySVP Controller
    Kind
  • Nov 4, 2026Jason PitofskySVP Controller
    Kind
  • Nov 3, 2026Andrew J MurphyCo-Chief Scientific Officer
    Kind
  • Nov 3, 2026Huda Y ZoghbiDirector
    Kind
  • Nov 3, 2026Huda Y ZoghbiDirector
    Kind
  • Nov 3, 2026Huda Y ZoghbiDirector
    Kind
  • Nov 2, 2026George L SingDirector
    Kind
  • Nov 2, 2026George L SingDirector
    Kind
  • Nov 2, 2026George L SingDirector
    Kind
  • Nov 2, 2026George L SingDirector
    Kind
  • Nov 2, 2026George L SingDirector
    Kind
  • Nov 2, 2026George L SingDirector
    Kind
  • Nov 2, 2026George L SingDirector
    Kind
  • Nov 2, 2026George L SingDirector
    Kind
  • Nov 2, 2026George L SingDirector
    Kind
  • Nov 2, 2026George L SingDirector
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jul 7, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by REGN's officers and directors from 2006 up to November 17, 2025, 20 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

1 Holders over 5%Apr 30, 2026 Latest filing
  • Vanguard Capital Management
    Share of class7.37%
Fell to 5% or less (3)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • The Vanguard Group0.00%Mar 27, 202613G/A
  • FMR3.20%Aug 6, 202513G/A
  • JPMorgan Chase4.40%Jun 5, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Southeastern Asset Mgmt
    In the quarter+17%
  • Renaissance Technologies
    In the quarter+84%
  • AQR Capital
    In the quarter-8.5%
  • Bridgewater (Dalio)
    In the quarter+126%
  • Millennium Mgmt (Englander)
    In the quarter+163%
  • Citadel Advisors (Griffin)
    In the quarter+21%
  • D.E. Shaw
    In the quarter+69%
  • Point72 (Cohen)
    In the quarter

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 2.04% of its shares outstanding were held short, -0.7% since the report before.

Shares held short
2.13M
2.04%
Since the report before2.15M on Sep 30, 2026
-0.7%
3.2
670.7K
More days to cover thanof 4,578 US-listed companies with enough volume
37%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 1.31M
  • Nov 15, 2023: Shares held short 1.40M
  • Nov 30, 2023: Shares held short 1.23M
  • Dec 15, 2023: Shares held short 1.22M
  • Dec 29, 2023: Shares held short 1.06M
  • Jan 12, 2024: Shares held short 1.07M
  • Jan 31, 2024: Shares held short 1.25M
  • Feb 15, 2024: Shares held short 1.37M
  • Feb 29, 2024: Shares held short 1.36M
  • Mar 15, 2024: Shares held short 1.39M
  • Mar 28, 2024: Shares held short 1.42M
  • Apr 15, 2024: Shares held short 1.39M
  • Apr 30, 2024: Shares held short 1.57M
  • May 15, 2024: Shares held short 1.63M
  • May 31, 2024: Shares held short 1.75M
  • Jun 14, 2024: Shares held short 1.85M
  • Jun 28, 2024: Shares held short 2.04M
  • Jul 15, 2024: Shares held short 1.89M
  • Jul 31, 2024: Shares held short 2.01M
  • Aug 15, 2024: Shares held short 2.11M
  • Aug 30, 2024: Shares held short 2.10M
  • Sep 13, 2024: Shares held short 1.98M
  • Sep 30, 2024: Shares held short 1.73M
  • Oct 15, 2024: Shares held short 1.72M
  • Oct 31, 2024: Shares held short 1.85M
  • Nov 15, 2024: Shares held short 1.79M
  • Nov 29, 2024: Shares held short 1.80M
  • Dec 13, 2024: Shares held short 1.88M
  • Dec 31, 2024: Shares held short 2.10M
  • Jan 15, 2025: Shares held short 2.12M
  • Jan 31, 2025: Shares held short 2.19M
  • Feb 14, 2025: Shares held short 2.20M
  • Feb 28, 2025: Shares held short 2.57M
  • Mar 14, 2025: Shares held short 3.25M
  • Mar 31, 2025: Shares held short 2.79M
  • Apr 15, 2025: Shares held short 2.60M
  • Apr 30, 2025: Shares held short 2.89M
  • May 15, 2025: Shares held short 2.80M
  • May 30, 2025: Shares held short 2.70M
  • Jun 13, 2025: Shares held short 2.03M
  • Jun 30, 2025: Shares held short 2.25M
  • Jul 15, 2025: Shares held short 2.07M
  • Jul 31, 2025: Shares held short 2.29M
  • Aug 15, 2025: Shares held short 2.35M
  • Aug 29, 2025: Shares held short 2.83M
  • Sep 15, 2025: Shares held short 2.99M
  • Sep 30, 2025: Shares held short 2.76M
  • Oct 15, 2025: Shares held short 2.93M
  • Oct 31, 2025: Shares held short 2.79M
  • Nov 14, 2025: Shares held short 2.84M
  • Nov 28, 2025: Shares held short 3.15M
  • Dec 15, 2025: Shares held short 2.74M
  • Dec 31, 2025: Shares held short 2.48M
  • Jan 15, 2026: Shares held short 2.29M
  • Jan 30, 2026: Shares held short 2.18M
  • Feb 13, 2026: Shares held short 2.05M
  • Feb 27, 2026: Shares held short 2.29M
  • Mar 13, 2026: Shares held short 2.45M
  • Mar 31, 2026: Shares held short 2.55M
  • Apr 15, 2026: Shares held short 2.84M
  • Apr 30, 2026: Shares held short 3.27M
  • May 15, 2026: Shares held short 2.78M
  • May 29, 2026: Shares held short 3.00M
  • Jun 15, 2026: Shares held short 3.30M
  • Jun 30, 2026: Shares held short 3.49M
  • Jul 15, 2026: Shares held short 3.50M
  • Jul 31, 2026: Shares held short 3.39M
  • Aug 14, 2026: Shares held short 2.40M
  • Aug 31, 2026: Shares held short 2.55M
  • Sep 15, 2026: Shares held short 2.53M
  • Sep 30, 2026: Shares held short 2.15M
  • Oct 15, 2026: Shares held short 2.13M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading45.6% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 45.6% of the shares in the reported trades were short sales, against 48.7% in the 14 before.

Last 14 sessionsOct 29, 2026 – Nov 17, 2026
45.6%
The 14 beforeOct 9, 2026 – Oct 28, 2026
48.7%
Change
-3.1 pts
Short sales a dayon average, of 460.6K shares
209.9K
More than atof 3,666 US-listed companies, same days
34%
Median of alleight in ten from 34.6% to 63.7%
50.3%
  • Oct 9, 2026: Short sales 46.7%
  • Oct 12, 2026: Short sales 39.2%
  • Oct 13, 2026: Short sales 42%
  • Oct 14, 2026: Short sales 47.5%
  • Oct 15, 2026: Short sales 50%
  • Oct 16, 2026: Short sales 40.7%
  • Oct 19, 2026: Short sales 57.1%
  • Oct 20, 2026: Short sales 60.7%
  • Oct 21, 2026: Short sales 58.7%
  • Oct 22, 2026: Short sales 58.1%
  • Oct 23, 2026: Short sales 43.5%
  • Oct 26, 2026: Short sales 38.5%
  • Oct 27, 2026: Short sales 40.1%
  • Oct 28, 2026: Short sales 57.4%
  • Oct 29, 2026: Short sales 58.6%
  • Oct 30, 2026: Short sales 48.8%
  • Nov 2, 2026: Short sales 55.3%
  • Nov 3, 2026: Short sales 53%
  • Nov 4, 2026: Short sales 27.5%
  • Nov 5, 2026: Short sales 38.3%
  • Nov 6, 2026: Short sales 34.4%
  • Nov 9, 2026: Short sales 39.1%
  • Nov 10, 2026: Short sales 37.4%
  • Nov 11, 2026: Short sales 53.9%
  • Nov 12, 2026: Short sales 47.8%
  • Nov 13, 2026: Short sales 42.5%
  • Nov 16, 2026: Short sales 35.1%
  • Nov 17, 2026: Short sales 49.6%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

1.72M Insiders' shares1.88% Of the company
  • George YancopoulosBd. Co-Chair, President & CSO
    Directly788.0K
  • Leonard S SchleiferBd. Co-Chair, President & CEO
    Directly466.9K
  • Neil StahlEVP Research and Development
    Directly56.1K
  • Andrew J MurphyEVP Research
    Directly51.2K
  • Joseph J LarosaEVP General Counsel and Secret
    Directly44.7K
  • George L SingDirector
    Directly27.3K
  • Christopher R. FenimoreSVP Finance & CFO
    Directly24.8K
  • Plew Daniel P VanEVP & General Mgr, Industrial
    Directly21.6K
  • Arthur F RyanDirector
    Directly17.3K
  • Michael S BrownDirector
    Directly12.9K
  • Marion McCourtEVP Commercial
    Directly11.1K
  • Joseph L GoldsteinDirector
    Directly6,382
  • Christine A PoonDirector
    Directly5,219
  • Jason PitofskySVP Controller
    Directly4,320
  • Huda Y ZoghbiDirector
    Directly1,703
  • Bonnie L BasslerDirector
    Directly1,703
  • Kathryn GuariniDirector
    Directly603

A lower bound: it counts only the 17 officers and directors with a market trade since Nov 19, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

10b5-1 trading plans

Since 2023 every 10-Q and 10-K says which insiders adopted or ended a trading plan (Rule 10b5-1) in the quarter: when, for how many shares, until when. A plan explains the sales that follow months before they show up on Form 4.

6 Adopted in the last 12 months15 Filings read
  • Andrew J. Murphy, Ph.DExecutive Vice President, Co-Chief Scientific Officer
    What happenedAdoptedMay 7, 2026
    Shares84.0K
  • Michael S. Brown, M.D.Director
    What happenedAdoptedFeb 25, 2026
    Shares1,929
  • Marion McCourtExecutive Vice President, Commercial
    What happenedAdoptedFeb 17, 2026
    Shares6,989
  • Kathryn Guarini, Ph.D.Director
    What happenedAdoptedFeb 13, 2026
    Shares1,600
  • Joseph L. Goldstein, M.D.Director
    What happenedAdoptedFeb 5, 2026
    Shares1,929
  • Huda Y. Zoghbi, M.D.Director
    What happenedAdoptedNov 20, 2025
    Shares2,438
  • Jason PitofskySenior Vice President, Controller
    What happenedAdoptedNov 10, 2025
    Shares3,261
  • Arthur F. RyanDirector
    What happenedAdoptedOct 31, 2025
    Shares1,200
  • Bonnie L. Bassler, Ph.D.Director
    What happenedAdoptedMay 2, 2025
    Shares5,121
  • Joseph L. Goldstein, M.D.Director
    What happenedAdoptedFeb 13, 2025
    Shares1,929

As the company states them in Item 9B of the 10-K and Part II, Item 5 of the 10-Q, with structured data. A plan allows sales on preset dates and prices. It does not say whether all of them will be executed.

Executive pay

From the Pay versus Performance table every company puts in its proxy statement since 2023: what the chief executive was paid, what was actually paid once the shares vest at year-end values, and how the stock did against the peer group the company itself picked.

2025 Latest year6 Years on record

$7.3M

Actually paid: $39M

$7.7M

Actually paid: $15M

$160

Peers: $201

stock price

From the proxy statement (DEF 14A) of Apr 24, 2026, as filed with the SEC with structured data. Pay in dollars. The company picks its own peer group and measure. DEF 14A

The shareholders' vote on pay

The advisory say-on-pay vote at each annual meeting, as the company states it in the 8-K it files after the meeting: how many voted for and against the executives' pay. 90% is the norm. Under 70% proxy advisers expect the board to respond the next year.

93.3% For in 20265 Votes on record
  • 2026Jun 17, 2026
    For
    93.3%
  • 2025Jun 18, 2025
    For
    93.3%
  • 2024Jun 20, 2024
    For
    95.0%
  • 2023Jun 14, 2023
    For
    87.1%
  • 2022Jun 15, 2022
    For
    87.8%

From the 8-K (item 5.07) the company files after each annual meeting since 2021, read from the filing's text without a model. A company that votes every three years has empty years. The vote is advisory: the board is not bound by it. 1 filing(s) not read, as the table is not in the usual shape.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

66 ETFs holding it4.91% The largest weight (IBB)
  • IBBiShares Biotechnology ETF
    Weight in the fund4.91%
  • PVALPutnam Focused Large Cap Value ETF
    Weight in the fund1.61%
  • COWZPacer US Cash Cows 100 ETF
    Weight in the fund1.36%
  • IYHiShares U.S. Healthcare ETF
    Weight in the fund1.27%
  • VHTVanguard Health Care Index Fund
    Weight in the fund1.15%
  • XLVState Street(R) Health Care Select Sector SPDR(R) ETF
    Weight in the fund1.08%
  • JEPIJPMorgan Equity Premium Income ETF
    Weight in the fund1.05%
  • RDVIFT Vest Rising Dividend Achievers Target Income ETF
    Weight in the fund1.04%
  • XBIState Street(R) SPDR(R) S&P(R) Biotech ETF
    Weight in the fund0.96%
  • CGGOCapital Group Global Growth Equity ETF
    Weight in the fund0.87%

66 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

1,335 Managers, Q2 2026$57.2B Value of their positions
  • Q3 2025: Managers 1,247
  • Q4 2025: Managers 1,389
  • Q1 2026: Managers 1,403
  • Q2 2026: Managers 1,335

Institutional investors by quarter

The fund managers holding REGN, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 1,335 managers held 91.59M shares, worth $57.2B. During the quarter 121 opened a position, 189 closed one, 477 added and 530 trimmed.

The largest holders, Q2 2026

  • BlackRock
    In the quarter+1.9%
  • Vanguard Capital Management
    In the quarter-0.4%
  • Dodge & Cox
    In the quarter+9.3%
  • State Street
    In the quarter+3.6%
  • Invesco
    In the quarter+0.9%
  • JPMorgan Chase
    In the quarter-12%
  • Vanguard Portfolio Management
    In the quarter+85%
  • Franklin Resources
    In the quarter+1.8%
  • Geode Capital Management
    In the quarter+0.7%
  • Nuveen
    In the quarter-2.2%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

The full analysis

What do Regeneron Pharmaceuticals's filings show?

Who buys and sells is one part of Regeneron Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about REGN's shareholders

Didn't find what you were looking for?

Ask us
Have REGN's insiders bought or sold?

From Jul 7, 2026 to Nov 6, 2026 Regeneron Pharmaceuticals's insiders bought 0 and sold $53M of shares on the market. 18% of the sales were under set 10b5-1 plans.

Which well-known managers hold REGN?

8 of the managers we track held the shares on Sep 30, 2026. The largest position was AQR Capital's, worth $702M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.